New frontiers in the design and synthesis of imaging probes for PET Oncology: Current challenges and future directions

Graham Smith, Laurence Carroll, Eric O. Aboagye

Research output: Contribution to journalReview article

Abstract

Despite being developed over 30 years ago, 2-deoxy-2-[18F] fluoro-D-glucose remains the most frequently used radiotracer in PET oncology. In the last decade, interest in new and more specific radiotracers for imaging biological processes of oncologic interest has increased exponentially. This review summarizes the strategies underlying the development of those probes together with their validation and status of clinical translation; a brief summary of new radiochemistry strategies applicable to PET imaging is also included. The article finishes with a consideration of the challenges imaging scientists must overcome to bring about increased adoption of PET as a diagnostic or pharmacologic tool.

Original languageEnglish (US)
Pages (from-to)653-666
Number of pages14
JournalMolecular Imaging and Biology
Volume14
Issue number6
DOIs
StatePublished - Dec 1 2012
Externally publishedYes

Fingerprint

Radiochemistry
Biological Phenomena
Fluorodeoxyglucose F18
Direction compound

Keywords

  • [ F]FDG
  • Positron emission tomography
  • Probe development
  • Therapy monitoring

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

New frontiers in the design and synthesis of imaging probes for PET Oncology : Current challenges and future directions. / Smith, Graham; Carroll, Laurence; Aboagye, Eric O.

In: Molecular Imaging and Biology, Vol. 14, No. 6, 01.12.2012, p. 653-666.

Research output: Contribution to journalReview article

@article{48384eb2b9944d7683a7d24c31128055,
title = "New frontiers in the design and synthesis of imaging probes for PET Oncology: Current challenges and future directions",
abstract = "Despite being developed over 30 years ago, 2-deoxy-2-[18F] fluoro-D-glucose remains the most frequently used radiotracer in PET oncology. In the last decade, interest in new and more specific radiotracers for imaging biological processes of oncologic interest has increased exponentially. This review summarizes the strategies underlying the development of those probes together with their validation and status of clinical translation; a brief summary of new radiochemistry strategies applicable to PET imaging is also included. The article finishes with a consideration of the challenges imaging scientists must overcome to bring about increased adoption of PET as a diagnostic or pharmacologic tool.",
keywords = "[ F]FDG, Positron emission tomography, Probe development, Therapy monitoring",
author = "Graham Smith and Laurence Carroll and Aboagye, {Eric O.}",
year = "2012",
month = "12",
day = "1",
doi = "10.1007/s11307-012-0590-y",
language = "English (US)",
volume = "14",
pages = "653--666",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - New frontiers in the design and synthesis of imaging probes for PET Oncology

T2 - Current challenges and future directions

AU - Smith, Graham

AU - Carroll, Laurence

AU - Aboagye, Eric O.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Despite being developed over 30 years ago, 2-deoxy-2-[18F] fluoro-D-glucose remains the most frequently used radiotracer in PET oncology. In the last decade, interest in new and more specific radiotracers for imaging biological processes of oncologic interest has increased exponentially. This review summarizes the strategies underlying the development of those probes together with their validation and status of clinical translation; a brief summary of new radiochemistry strategies applicable to PET imaging is also included. The article finishes with a consideration of the challenges imaging scientists must overcome to bring about increased adoption of PET as a diagnostic or pharmacologic tool.

AB - Despite being developed over 30 years ago, 2-deoxy-2-[18F] fluoro-D-glucose remains the most frequently used radiotracer in PET oncology. In the last decade, interest in new and more specific radiotracers for imaging biological processes of oncologic interest has increased exponentially. This review summarizes the strategies underlying the development of those probes together with their validation and status of clinical translation; a brief summary of new radiochemistry strategies applicable to PET imaging is also included. The article finishes with a consideration of the challenges imaging scientists must overcome to bring about increased adoption of PET as a diagnostic or pharmacologic tool.

KW - [ F]FDG

KW - Positron emission tomography

KW - Probe development

KW - Therapy monitoring

UR - http://www.scopus.com/inward/record.url?scp=84870468843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870468843&partnerID=8YFLogxK

U2 - 10.1007/s11307-012-0590-y

DO - 10.1007/s11307-012-0590-y

M3 - Review article

C2 - 22948535

AN - SCOPUS:84870468843

VL - 14

SP - 653

EP - 666

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 6

ER -